Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-104 versus Stalevo in Parkinson's disease with end-of-dose wearing-off
2015-004507-23Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of neluxicapone in Parkinson's disease (PD) (2 arms), sponsored by Orion Corporation. Primary endpoint: Primary efficacy endpoint. Started Jan 2016; status: completed.
02
Drugs
neluxicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2015-004507-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004507-23.